|
2012-09-06 |
2012-09-05 |
B
Compra
|
SPECTRUM PHARMACEUTICALS INC
Gran accionista
|
57 126
+34.3%
475,70
4.477.801 US$
|
57 126
+34.3%
|
475,70
|
4.477.801 US$
|
|
|
2012-03-01 |
2012-03-01 |
Por favor
Venta prevista
|
BENNETT BRUCE K JR
VP, Pharmaceutical Operations
Oficial
|
8 268
-11.5%
198,88
3.779.526 US$
|
8 268
-11.5%
|
198,88
|
3.779.526 US$
|
|
|
2012-03-01 |
2012-02-29 |
Por favor
Venta prevista
|
BENNETT BRUCE K JR
VP, Pharmaceutical Operations
Oficial
|
41 087
+32.2%
75,81
4.606.948 US$
|
41 087
+32.2%
|
75,81
|
4.606.948 US$
|
|
|
2012-02-27 |
2012-02-24 |
Por favor
Venta prevista
|
BENNETT BRUCE K JR
VP, Pharmaceutical Operations
Oficial
|
1 469
-1.3%
1,55
2.277 US$
|
1 469
-1.3%
|
1,55
|
2.277 US$
|
|
|
2011-02-25 |
2011-02-24 |
Por favor
Venta prevista
|
BENNETT BRUCE K JR
VP, Pharmaceutical Operations
Oficial
|
1 469
-1.5%
3,20
4.701 US$
|
1 469
-1.5%
|
3,20
|
4.701 US$
|
|
|
2010-05-12 |
2010-05-10 |
Por favor
Venta prevista
|
Clark David C
VP, Finance
Oficial
|
3 085
-15.3%
7,03
21.684 US$
|
3 085
-15.3%
|
7,03
|
21.684 US$
|
|
|
2010-04-14 |
2010-04-12 |
Por favor
Venta prevista
|
Graboyes Marc H
SVP, General Counsel
Oficial
|
75 000
-56.4%
8,58
643.530 US$
|
75 000
-56.4%
|
8,58
|
643.530 US$
|
|
|
2010-03-12 |
2010-03-10 |
Por favor
Venta prevista
|
Clark David C
VP, Finance
Oficial
|
20 000
-50.8%
7,78
155.612 US$
|
20 000
-50.8%
|
7,78
|
155.612 US$
|
|
|
2010-03-08 |
2010-03-05 |
Por favor
Venta prevista
|
Clark David C
VP, Finance
Oficial
|
10 000
-34.1%
7,02
70.196 US$
|
10 000
-34.1%
|
7,02
|
70.196 US$
|
|
|
2010-03-08 |
2010-03-04 |
Por favor
Venta prevista
|
Clark David C
VP, Finance
Oficial
|
11 640
-37.6%
6,98
81.301 US$
|
11 640
-37.6%
|
6,98
|
81.301 US$
|
|
|
2010-03-03 |
2010-03-01 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
37 500
-26.6%
8,13
304.875 US$
|
37 500
-26.6%
|
8,13
|
304.875 US$
|
|
|
2010-03-03 |
2010-03-01 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
40 000
-22.1%
8,13
325.204 US$
|
40 000
-22.1%
|
8,13
|
325.204 US$
|
|
|
2010-02-24 |
2010-02-24 |
Por favor
Venta prevista
|
BERNS PAUL L
Chief Executive Officer
Oficial
|
7 362
-3.2%
7,57
55.766 US$
|
7 362
-3.2%
|
7,57
|
55.766 US$
|
|
|
2010-02-24 |
2010-02-24 |
Por favor
Venta prevista
|
Graboyes Marc H
SVP, General Counsel
Oficial
|
2 349
-3.9%
7,44
17.477 US$
|
2 349
-3.9%
|
7,44
|
17.477 US$
|
|
|
2010-02-24 |
2010-02-23 |
Por favor
Venta prevista
|
BERNS PAUL L
Chief Executive Officer
Oficial
|
4 304
-1.8%
7,51
32.331 US$
|
4 304
-1.8%
|
7,51
|
32.331 US$
|
|
|
2010-02-24 |
2010-02-23 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
5 968
-4.1%
7,44
44.378 US$
|
5 968
-4.1%
|
7,44
|
44.378 US$
|
|
|
2010-02-24 |
2010-02-23 |
Por favor
Venta prevista
|
Graboyes Marc H
SVP, General Counsel
Oficial
|
1 416
-2.3%
7,51
10.634 US$
|
1 416
-2.3%
|
7,51
|
10.634 US$
|
|
|
2010-02-24 |
2010-02-23 |
Por favor
Venta prevista
|
BENNETT BRUCE K JR
VP, Pharmaceutical Operations
Oficial
|
1 468
-6.0%
7,51
11.025 US$
|
1 468
-6.0%
|
7,51
|
11.025 US$
|
|
|
2010-01-11 |
2010-01-11 |
Por favor
Venta prevista
|
HOFFMAN STEPHEN J
Consejero no ejecutivo
|
45 428
-8.7%
7,30
331.738 US$
|
45 428
-8.7%
|
7,30
|
331.738 US$
|
|
|
2010-01-11 |
2010-01-08 |
Por favor
Venta prevista
|
HOFFMAN STEPHEN J
Consejero no ejecutivo
|
45 429
-8.7%
7,11
322.918 US$
|
45 429
-8.7%
|
7,11
|
322.918 US$
|
|
|
2010-01-11 |
2010-01-07 |
Por favor
Venta prevista
|
HOFFMAN STEPHEN J
Consejero no ejecutivo
|
45 429
-8.7%
6,76
307.114 US$
|
45 429
-8.7%
|
6,76
|
307.114 US$
|
|
|
2010-01-06 |
2010-01-06 |
Por favor
Venta prevista
|
HOFFMAN STEPHEN J
Consejero no ejecutivo
|
45 429
-8.7%
6,78
308.163 US$
|
45 429
-8.7%
|
6,78
|
308.163 US$
|
|
|
2010-01-06 |
2010-01-05 |
Por favor
Venta prevista
|
HOFFMAN STEPHEN J
Consejero no ejecutivo
|
45 428
-8.7%
6,64
301.497 US$
|
45 428
-8.7%
|
6,64
|
301.497 US$
|
|
|
2010-01-06 |
2010-01-04 |
Por favor
Venta prevista
|
HOFFMAN STEPHEN J
Consejero no ejecutivo
|
25 428
-5.1%
6,54
166.220 US$
|
25 428
-5.1%
|
6,54
|
166.220 US$
|
|
|
2009-08-12 |
2009-08-10 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
85 400
-49.0%
8,13
694.302 US$
|
85 400
-49.0%
|
8,13
|
694.302 US$
|
|
|
2009-08-12 |
2009-08-10 |
Por favor
Venta prevista
|
BERNS PAUL L
Chief Executive Officer
Oficial
|
342 000
-59.6%
8,24
2.819.311 US$
|
342 000
-59.6%
|
8,24
|
2.819.311 US$
|
|
|
2009-08-07 |
2009-08-05 |
Por favor
Venta prevista
|
BERNS PAUL L
Chief Executive Officer
Oficial
|
8 000
-3.3%
8,14
65.150 US$
|
8 000
-3.3%
|
8,14
|
65.150 US$
|
|
|
2009-08-05 |
2009-08-05 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
14 600
-14.1%
8,13
118.755 US$
|
14 600
-14.1%
|
8,13
|
118.755 US$
|
|
|
2009-08-05 |
2009-08-03 |
Por favor
Venta prevista
|
Graboyes Marc H
VP, General Counsel
Oficial
|
50 000
-71.4%
8,00
400.000 US$
|
50 000
-71.4%
|
8,00
|
400.000 US$
|
|
|
2009-08-05 |
2009-08-03 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
50 000
-36.0%
7,79
389.480 US$
|
50 000
-36.0%
|
7,79
|
389.480 US$
|
|
|
2009-03-27 |
2009-03-26 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
39 500
-25.3%
7,37
291.206 US$
|
39 500
-25.3%
|
7,37
|
291.206 US$
|
|
|
2009-03-27 |
2009-03-25 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
6 900
-5.6%
7,13
49.209 US$
|
6 900
-5.6%
|
7,13
|
49.209 US$
|
|
|
2009-03-16 |
2009-03-16 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
3 600
-3.0%
7,13
25.674 US$
|
3 600
-3.0%
|
7,13
|
25.674 US$
|
|
|
2009-03-16 |
2009-03-13 |
Por favor
Venta prevista
|
Clark David C
VP, Finance
Oficial
|
5 027
-41.3%
7,00
35.189 US$
|
5 027
-41.3%
|
7,00
|
35.189 US$
|
|
|
2009-03-16 |
2009-03-13 |
Por favor
Venta prevista
|
Graboyes Marc H
VP, General Counsel
Oficial
|
5 864
-22.6%
7,00
41.048 US$
|
5 864
-22.6%
|
7,00
|
41.048 US$
|
|
|
2009-03-16 |
2009-03-12 |
Por favor
Venta prevista
|
Clark David C
VP, Finance
Oficial
|
64 973
-90.1%
7,02
455.812 US$
|
64 973
-90.1%
|
7,02
|
455.812 US$
|
|
|
2009-03-16 |
2009-03-12 |
Por favor
Venta prevista
|
CARUSO JAMES V
Chief Commercial Officer
Oficial
|
50 000
-30.1%
7,13
356.500 US$
|
50 000
-30.1%
|
7,13
|
356.500 US$
|
|
|
2009-03-16 |
2009-03-12 |
Por favor
Venta prevista
|
Graboyes Marc H
VP, General Counsel
Oficial
|
69 136
-77.5%
7,02
485.010 US$
|
69 136
-77.5%
|
7,02
|
485.010 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
22
-0.0%
8,26
182 US$
|
22
-0.0%
|
8,26
|
182 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
24 857
-11.5%
8,17
203.176 US$
|
24 857
-11.5%
|
8,17
|
203.176 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
1
-0.0%
8,26
8 US$
|
1
-0.0%
|
8,26
|
8 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
705
-11.5%
8,17
5.763 US$
|
705
-11.5%
|
8,17
|
5.763 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
235
-0.0%
8,26
1.940 US$
|
235
-0.0%
|
8,26
|
1.940 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
263 312
-11.5%
8,17
2.152.260 US$
|
263 312
-11.5%
|
8,17
|
2.152.260 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
Baker Bros. Capital (GP), LLC
Gran accionista
|
212
-11.5%
8,17
1.733 US$
|
212
-11.5%
|
8,17
|
1.733 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
8
-0.0%
8,26
66 US$
|
8
-0.0%
|
8,26
|
66 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
9 380
-11.5%
8,17
76.670 US$
|
9 380
-11.5%
|
8,17
|
76.670 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
670
-0.0%
8,26
5.532 US$
|
670
-0.0%
|
8,26
|
5.532 US$
|
|
|
2009-02-06 |
2009-02-06 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
751 534
-11.5%
8,17
6.142.889 US$
|
751 534
-11.5%
|
8,17
|
6.142.889 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
4 725
-2.1%
8,11
38.299 US$
|
4 725
-2.1%
|
8,11
|
38.299 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
1 200
-0.5%
8,17
9.806 US$
|
1 200
-0.5%
|
8,17
|
9.806 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
6 392
-2.8%
8,16
52.180 US$
|
6 392
-2.8%
|
8,16
|
52.180 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
134
-2.1%
8,11
1.086 US$
|
134
-2.1%
|
8,11
|
1.086 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
34
-0.5%
8,17
278 US$
|
34
-0.5%
|
8,17
|
278 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
181
-2.8%
8,16
1.478 US$
|
181
-2.8%
|
8,16
|
1.478 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
50 041
-2.1%
8,11
405.617 US$
|
50 041
-2.1%
|
8,11
|
405.617 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
12 713
-0.5%
8,17
103.882 US$
|
12 713
-0.5%
|
8,17
|
103.882 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
67 709
-2.8%
8,16
552.729 US$
|
67 709
-2.8%
|
8,16
|
552.729 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Bros. Capital (GP), LLC
Gran accionista
|
40
-2.1%
8,11
324 US$
|
40
-2.1%
|
8,11
|
324 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Bros. Capital (GP), LLC
Gran accionista
|
10
-0.5%
8,17
82 US$
|
10
-0.5%
|
8,17
|
82 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Bros. Capital (GP), LLC
Gran accionista
|
55
-2.8%
8,16
449 US$
|
55
-2.8%
|
8,16
|
449 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
1 782
-2.1%
8,11
14.444 US$
|
1 782
-2.1%
|
8,11
|
14.444 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
453
-0.5%
8,17
3.702 US$
|
453
-0.5%
|
8,17
|
3.702 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
2 411
-2.8%
8,16
19.682 US$
|
2 411
-2.8%
|
8,16
|
19.682 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
142 827
-2.1%
8,11
1.157.713 US$
|
142 827
-2.1%
|
8,11
|
1.157.713 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
36 286
-0.5%
8,17
296.504 US$
|
36 286
-0.5%
|
8,17
|
296.504 US$
|
|
|
2009-02-06 |
2009-02-05 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
193 252
-2.8%
8,16
1.577.574 US$
|
193 252
-2.8%
|
8,16
|
1.577.574 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
24 256
-9.6%
8,46
205.191 US$
|
24 256
-9.6%
|
8,46
|
205.191 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
2 593
-1.0%
8,47
21.961 US$
|
2 593
-1.0%
|
8,47
|
21.961 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
269
-0.1%
9,03
2.430 US$
|
269
-0.1%
|
9,03
|
2.430 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
688
-9.6%
8,46
5.820 US$
|
688
-9.6%
|
8,46
|
5.820 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
74
-1.0%
8,47
627 US$
|
74
-1.0%
|
8,47
|
627 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
BAKER JULIAN
Gran accionista
|
8
-0.1%
9,03
72 US$
|
8
-0.1%
|
9,03
|
72 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
256 936
-9.6%
8,46
2.173.524 US$
|
256 936
-9.6%
|
8,46
|
2.173.524 US$
|
|
|
2009-02-06 |
2009-02-04 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
27 485
-1.1%
8,47
232.781 US$
|
27 485
-1.1%
|
8,47
|
232.781 US$
|
|